Zilbrysq
Evidence Grade A — Regulatory approved. 80 published studies. 19 registered clinical trials.
Loading...
Zilucoplan (sold as Zilbrysq) is a self-injectable treatment for generalised myasthenia gravis — a condition where the immune system attacks the connections between nerves and muscles, causing fluctuating weakness that can affect breathing, swallowing, and movement. Its key advantage over existing treatments is that patients can inject it themselves at home daily, rather than needing hospital visits for intravenous infusions.
80 published studies: 50 human, 0 animal, 4 in-vitro, 29 reviews
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection.
In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
In antibody-positive myasthenia gravis, immune antibodies against the acetylcholine receptor activate the complement system — a destructive cascade of immune proteins. The final step of this cascade creates a 'membrane attack complex' (MAC) that punches holes in the muscle cell membrane at the neuromuscular junction, destroying the receptor-rich folds that receive nerve signals. Zilucoplan blocks complement component C5, preventing both the formation of the MAC and the release of the inflammatory signal C5a, halting the destruction.
The RAISE trial showed statistically significant improvements in both daily activities and muscle strength scores compared to placebo, with benefits appearing within the first week. As a small synthetic peptide (approximately 40 times smaller than the antibody-based complement inhibitors eculizumab and ravulizumab), zilucoplan can be delivered as a subcutaneous injection rather than requiring IV infusions. As with all complement inhibitors, patients must be vaccinated against meningococcal bacteria at least two weeks before starting treatment, because the drug reduces the immune system's ability to fight these infections. Data are currently limited to 12 weeks, with no head-to-head comparisons against existing treatments (eculizumab, ravulizumab, or efgartigimod). The self-administration convenience is the primary differentiator in a field where existing treatments work well but require hospital-based infusions.
Zilucoplan for Severe gMG Exacerbations
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
FDA ORIG 1
EMA Marketing Authorisation
FDA SUPPL 4
FDA SUPPL 1
FDA SUPPL 9
FDA SUPPL 8
Health Canada Market Authorisation
FDA SUPPL 13
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
